<table id="Table4" width="90%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Established and Other Potentially Significant<footnote>This table is not all inclusive.</footnote> Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction</caption>
<col align="left" valign="top" width="30%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="45%"></col>
<thead>
<tr>
<th stylecode="Lrule Rrule">Concomitant  Drug Class: Drug Name</th>
<th align="center" stylecode="Rrule">Effect on Concentration<footnote>Increase=↑; Decrease=↓; No Effect=↔</footnote>
</th>
<th align="center" stylecode="Rrule" valign="middle">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antacids:</content>
<br/>  antacids (e.g., aluminium, magnesium hydroxide, or calcium carbonate)</td>
<td stylecode="Rrule">↔ rilpivirine (antacids taken at least 2 hours before or at least 4 hours after rilpivirine)<br/>↓ rilpivirine (concomitant intake)</td>
<td stylecode="Rrule">The combination of COMPLERA and antacids should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Antacids should only be administered either at least 2 hours before or at least 4 hours after COMPLERA.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterials:</content>
<br/>  rifabutin</td>
<td stylecode="Rrule">↓ rilpivirine<footnote id="t4fc">The interaction was evaluated in a clinical study. All other drug-drug interactions shown are predicted.</footnote>
</td>
<td stylecode="Rrule">Concomitant use of COMPLERA with rifabutin may cause significant decreases in rilpivirine plasma concentrations (induction of CYP3A enzymes). If COMPLERA is coadministered with rifabutin, an additional 25 mg tablet of rilpivirine (Edurant) once per day is recommended to be taken concomitantly with COMPLERA and with a meal for the duration of rifabutin coadministration.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Azole Antifungal Agents:<br/>
</content>  fluconazole<br/>  itraconazole<br/>  ketoconazole<br/>  posaconazole<br/>  voriconazole</td>
<td stylecode="Rrule">↑ rilpivirine<footnoteref idref="t4fc"></footnoteref>
<sup>,</sup>
<footnote id="t4fd">This interaction study has been performed with a dose higher than the recommended dose for rilpivirine. The dosing recommendation is applicable to the recommended dose of rilpivirine 25 mg once daily.</footnote>
<br/>↓ ketoconazole<footnoteref idref="t4fc"></footnoteref>
<sup>,</sup>
<footnoteref idref="t4fd"></footnoteref>
</td>
<td stylecode="Rrule">Concomitant use of COMPLERA with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). No dose adjustment is required when COMPLERA is coadministered with azole antifungal agents. Clinically monitor for breakthrough fungal infections when azole antifungals are coadministered with COMPLERA.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Hepatitis C Antiviral Agents:</content>
<br/>  ledipasvir/sofosbuvir<br/>  sofosbuvir/velpatasvir</td>
<td stylecode="Rrule">↑ tenofovir<footnoteref idref="t4fc"></footnoteref>
</td>
<td stylecode="Rrule">Patients receiving COMPLERA concomitantly with HARVONI<sup>® </sup>(ledipasvir/sofosbuvir) or EPCLUSA<sup>®</sup> (sofosbuvir/velpatasvir) should be monitored for adverse reactions associated with tenofovir DF.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">H<sub>2</sub>-Receptor Antagonists:</content>
<br/>  cimetidine<br/>  famotidine<br/>  nizatidine<br/>  ranitidine</td>
<td stylecode="Rrule">↔ rilpivirine<footnoteref idref="t4fc"></footnoteref>
<sup>,</sup>
<footnoteref idref="t4fd"></footnoteref> (famotidine taken 12 hours before rilpivirine or 4 hours after rilpivirine)<br/>↓ rilpivirine<footnoteref idref="t4fc"></footnoteref>
<sup>,</sup>
<footnoteref idref="t4fd"></footnoteref> (famotidine taken 2 hours before rilpivirine)</td>
<td stylecode="Rrule">The combination of COMPLERA and H<sub>2</sub>-receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). H<sub>2</sub>-receptor antagonists should only be administered at least 12 hours before or at least 4 hours after COMPLERA.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Macrolide or Ketolide Antibiotics:</content>
<br/>  clarithromycin<br/>  erythromycin<br/>  telithromycin</td>
<td stylecode="Rrule">↑  rilpivirine<br/>↔ clarithromycin <br/>↔ erythromycin<br/> ↔ telithromycin</td>
<td stylecode="Rrule">Concomitant use of COMPLERA with clarithromycin, erythromycin, or telithromycin may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes). Where possible, alternatives such as azithromycin should be considered.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic Analgesics</content>:<br/>  methadone</td>
<td stylecode="Rrule">↓ R(–) methadone<footnoteref idref="t4fc"></footnoteref>
<br/>↓ S(+) methadone<footnoteref idref="t4fc"></footnoteref>
<br/>↔ rilpivirine<footnoteref idref="t4fc"></footnoteref>
<br/>↔ methadone<footnoteref idref="t4fc"></footnoteref> (when used with tenofovir)</td>
<td stylecode="Rrule">No dose adjustments are required when initiating coadministration of methadone with COMPLERA. However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients.</td>
</tr>
</tbody>
</table>